Semaphorin 7A in circulating regulatory T cells is increased in autosomal-dominant polycystic kidney disease and decreases with tolvaptan treatment
Sign Up to like & getrecommendations! Published in 2018 at "Clinical and Experimental Nephrology"
DOI: 10.1007/s10157-018-1542-x
Abstract: BackgroundSemaphorin 7A (SEMA7A) is an immunomodulating protein implicated in lung and liver fibrosis. In autosomal-dominant polycystic kidney disease (ADPKD), the progressive expansion of renal cysts, inflammation, and subsequent renal fibrosis leads to end-stage renal disease… read more here.
Keywords: fibrosis; disease; expression; tolvaptan treatment ... See more keywords
Early Commencement and Long-Term Continuation of Tolvaptan Treatment Attenuate Functional Impairment of Renal Vasopressin V2 Receptors and Improve Clinical Outcomes in Patients with Heart Failure.
Sign Up to like & getrecommendations! Published in 2023 at "International heart journal"
DOI: 10.1536/ihj.22-321
Abstract: Preserved urinary excretion of aquaporin 2, an index for the function of vasopressin V2 receptor (V2-R), has been reported to predict a favorable response of heart failure patients to treatment with tolvaptan. In this study,… read more here.
Keywords: long term; high uosm; heart; treatment ... See more keywords
Serum Copeptin and Zinc-α2-glycoprotein Levels Are Novel Biomarkers of Tolvaptan Treatment in Decompensated Cirrhotic Patients with Ascites.
Sign Up to like & getrecommendations! Published in 2021 at "Internal medicine"
DOI: 10.2169/internalmedicine.7291-21
Abstract: Objective The efficacy of tolvaptan, an orally active vasopressin V2-receptor antagonist, has recently been reported in patients with massive ascites unresponsive to conventional diuretics. However, the effect of tolvaptan varies among patients. Recently, the prognostic… read more here.
Keywords: serum copeptin; copeptin; zag; treatment ... See more keywords